Can-Fite BioPharma (CANF) announces the dosing of the first patient in the Phase IIa clinical trial in patients with advanced pancreatic adenocarcinoma. “We are excited to have the first patient enrolled and hope that we will be able to demonstrate the safety and efficacy of Namodenoson in the pancreatic cancer patient population. This trial provides us the opportunity to explore our innovative treatment approach for patients who are facing significant gaps in effective treatment options,” stated Dr. Michael Silverman, Can-Fite’s Medical Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANF:
- Can-Fite BioPharma Secures Australian Patent for Obesity Drug
- Can-Fite BioPharma announces an update related to IP status of Namodenoson
- Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix
- Can-Fite BioPharma reports results from osteoarthritis clinical study in dogs
- Can-Fite’s Namodenoson Gains FDA Orphan Status
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
